Skip to main content
OpenTrials

Clinical trial condition

Renal Cell Carcinoma

Explore clinical trials studying Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

412 public trials 75 recruiting studies
Refine in advanced search Browse all conditions

Renal Cell Carcinoma trial results

Active, Not Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • UC Irvine Medical Center Orange, California, United States
  • Sibley Memorial Hospital Washington D.C., District of Columbia, United States
  • Emory University Atlanta, Georgia, United States
View all 44 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • The Second Hospital and Clinical Medical School, Lanzhou University Lanzhou, Gansu, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 18 locations
View Trial Details
Active, Not Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

NCT05858736

Conditions
Adenocarcinoma, Adnexal Diseases, Anal Cancer, +85 more
Locations
  • St. Vincent's Private Hospital Darlinghurst, New South Wales, Australia
  • Mater Misericordiae Ltd. Brisbane, Queensland, Australia
  • Tasman Oncology Research Southport, Queensland, Australia
  • Cancer Research SA Adelaide, South Australia, Australia
View Trial Details
Active, Not Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +32 more
Locations
  • Russell Medical ( Site 0160) Alexander City, Alabama, United States
  • Alaska Oncology and Hematology ( Site 0121) Anchorage, Alaska, United States
  • Highlands Oncology Group-Research Department ( Site 0133) Springdale, Arkansas, United States
  • Marin Cancer Care ( Site 0148) Greenbrae, California, United States
View all 45 locations
View Trial Details
Active, Not Recruiting

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

NCT05703269

Conditions
Adenocarcinoma, Brain Diseases, Brain Metastases, Adult, +46 more
Locations
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • Crossroads Cancer Center Effingham, Illinois, United States
  • HSHS Saint Elizabeth's Hospital O'Fallon, Illinois, United States
View all 34 locations
View Trial Details

Related conditions